Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations
2011 ◽
Vol 41
(8)
◽
pp. 959-963
◽
S. Matsuura
◽
N. Inui
◽
Y. Ozawa
◽
Y. Nakamura
◽
M. Toyoshima
◽
...
Shun Matsuura
◽
Naoki Inui
◽
Yuichi Ozawa
◽
Toshihiro Shirai
◽
Mikio Toyoshima
◽
...
2007 ◽
Vol 2
(8)
◽
pp. S733-S734
Hyewon Lee
◽
Hoyong Sim
◽
Se Hoon Park
◽
Jinny Park
◽
Eun Kyung Cho
◽
...
2018 ◽
Vol 29
◽
pp. viii493
◽
Y. Cheng
◽
J. Zhou
◽
S. Lu
◽
Y. Zhang
◽
J. Zhao
◽
...
2015 ◽
Vol 76
(1)
◽
pp. 155-161
◽
Yusuke Inoue
◽
Naoki Inui
◽
Kazuhiro Asada
◽
Masato Karayama
◽
Hiroyuki Matsuda
◽
...
2014 ◽
Vol 32
(15_suppl)
◽
pp. e19095-e19095
Akihiro Tamiya
◽
Motohiro Tamiya
◽
Takeshi Nakatani
◽
Takayuki Shiroyama
◽
Kanako Kitai
◽
...
2002 ◽
Vol 38
◽
pp. S153
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7559-7559
S. Fujita
◽
N. Katakami
◽
K. Masago
◽
H. Yoshioka
◽
K. Tomii
◽
...
2021 ◽
Vol 16
(3)
◽
pp. S449
B. Melosky
◽
E. Laack
◽
K. Kambartel
◽
M. Häntschel
◽
M. Bennetts
◽
...
Close
Export Citation Format
Close
Share Document
Close